Summary: Landiolol hydrochloride is a newly developed cardioselective, ultra short-acting b1-adrenergic receptor blocking agent used for perioperative arrhythmia control. The objective of this study was to characterize the population pharmacokinetics of landiolol hydrochloride in healthy male subjects. A total of 420 blood concentration data points collected from 47 healthy male subjects were used for the population pharmacokinetic analysis. NONMEM was used for population pharmacokinetic analysis. In addition, the final pharmacokinetic model was evaluated using a bootstrap method and a leave-one-out cross validation method. The concentration time course of landiolol hydrochloride was best described by a two-compartment model with lag time. The final parameters were total body clearance (CL: 36.6 mL/min/kg), distribution volume of the central compartment (V1: 101 mL/kg), inter-compartmental clearance (16.1 mL/min/kg), distribution volume of the peripheral compartment (55.6 mL/kg), and lag time (0.82 min). The inter-individual variability in the CL and V1 were 21.8z and 46.3z, respectively. The residual variability was 22.1z. Model evaluation by the two different methods indicated that the final model was robust and parameter estimates were reasonable. The population pharmacokinetic model for landiolol hydrochloride in healthy subjects was developed and was shown to be appropriate by both bootstrap and leave-one-out cross validation methods.
Introduction
Since perioperative hemodynamics constantly vary with the administration of multiple drugs and operative stress, a transient strong sympathetic stimulation such as endotracheal intubation and surgical incision may induce acute tachycardia and hypertension. b-adrenergic receptor blocking agents are useful for the prevention of myocardial ischemia in patients with tachycardia and are effective in reducing mortality and cardiovascular complications. 1) The possibility of adverse events such as bradycardia, hypotension, heart block, bronchospasm, and heart failure is an undesirable feature of b-adrenergic receptor blocking agents with relatively long elimination half-life (e.g., propranolol). Esmolol, the first ultra short-acting b1-adrenergic receptor blocking agent, has been widely used to control stress-induced tachycardia during general anesthesia.
Landiolol hydrochloride is a newly developed cardioselective, ultra short-acting b1-adrenergic receptor blocking agent. This drug is rapidly hydrolyzed to an inactive form by both carboxylesterase in the liver and Table 1 . Sources of blood landiolol hydrochloride concentration data used in the population analysis 1-min loading infusion at 250 mg/kg/min, followed by a 60-min continuous infusion at 40 mg/kg/min 5 48 9.6/subject 1-min loading infusion at 500 mg/kg/min, followed by a 60-min continuous infusion at 80 mg/kg/min a Dose L (1-min loading infusion at 30 mg/kg/min followed by a 10-min continuous infusion at 10 mg/kg/min) to Dose M (1-min loading infusion at 60 mg/kg/min followed by a 10-min continuous infusion at 20 mg/kg/min) b Dose M to Dose H (1-min loading infusion at 125 mg/kg/min followed by a 10-min continuous infusion at 40 mg/kg/min)
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pseudocholinesterase in the plasma, resulting in an elimination half-life of about 4 min.
2)
Landiolol hydrochloride has a much higher cardioselectivity (b1/b2＝255) than esmolol (b1/b2＝33), and seems to have little effect on the respiratory system. 3) Based on these features, landiolol hydrochloride has been used in the emergency management of atrial fibrillation, atrial flutter and tachycardia as well as in perioperative arrhythmia control.
The introduction of a target controlled infusion (TCI) system into clinical practice ensures that a target plasma drug concentration is obtained to induce and maintain anesthesia during perioperative anesthetic management. The TCI system involves computer control of an infusion pump, and permits computer-assisted intravenous administration of drugs used in anesthesia (e.g., sedatives, analgesics, and muscle relaxants) according to their pharmacokinetic profiles. [4] [5] [6] [7] Based on a pharmacokinetic model, the TCI system determines the initial loading dose needed to achieve a target plasma drug concentration and the infusion rate needed to maintain a constant concentration, and controls the intravenous infusion completely automatically. 8, 9) Therefore, application of the TCI system to landiolol hydrochloride administration is expected to allow more effective and safe drug administration. However, a pharmacokinetic model of landiolol hydrochloride is necessary for the application of the TCI system and has not previously been reported. In this study, a population pharmacokinetic analysis was performed to develop a pharmacokinetic model of landiolol hydrochloride using blood concentration data obtained from Phase I studies.
Methods
Subjects and studies: A total of 420 blood concentration data points were collected from 47 healthy male subjects who participated in three clinical trials (studies 1-3) conducted in Japan (Table 1) . 2, 10) Studies 1-3 were performed to evaluate pharmacokinetics and safety of different landiolol usages which were infusion, loading＋ infusion, and a two-dose escalation regimen. Subjects were between 20 and 33 years of age, between 50.7 and 77.2 kg, and were determined to be in good health based on medical history, physical examination, vital signs, electrocardiograms, and laboratory test values. The study protocols were reviewed and approved by the Institutional Review Boards of each clinical study site. Written informed consent was obtained from each subject.
Study 1 consists of the pilot study, single dose study, and multiple dose study. In the pilot study, landiolol hydrochloride was administered to two subjects in each group at an infusion rate of 5, 10, 20, 40, or 80 mg/kg/min for 60 min. Blood samples were drawn from the vein of each subject at 0, 15, 30, and 60 min after initiation of administration, and 2, 5, 10, 15, and 30 min, and 2, 12, and 24 h after completion of administration. In the single dose study, landiolol hydrochloride was administered to 10 subjects at an infusion rate of 40 or 80 mg/kg/min for 60 min. Blood samples were drawn from the vein of each subject at 0, 2, 5, 15, 30, and 60 min after initiation of administration, and 2, 5, 10, 15, and 30 min, and 1, 2, 4, 8, 12, and 24 h after completion of administration. In the multiple dose study, landiolol hydrochloride was administered to five subjects at an infusion rate of 80 mg/kg/min for 60 min at an interval of 10 h. Blood samples were drawn from the vein of each subject at 0 and 60 min after initiation of the first administration, and 5 and 15 min, and 1 and 4 h after completion of the first administration, as well as 0, 5, 15, 30, and 60 min after initiation of the second administration, and 5, 10, 15, and 30 min, and 1, 2, 4, and 12 h after completion of the second administration.
In Study 2, to immediately achieve a steady state level of blood landiolol hydrochloride concentration, a loading dose was added following the infusion. 10 subjects were randomly allocated to group 1 (a 1-min loading infusion at 250 mg/kg/min, followed by a 60-min continuous infusion at 40 mg/kg/min), and group 2 (a 1-min loading infusion at 500 mg/kg/min, followed by a 60-min continuous infusion at 80 mg/kg/min). Eighteen blood samples were drawn from the vein of each subject before dosing, and at 1, 2, 5, 15, 30, and 61 min after initiation of administration, and at 2, 5, 10, 15, and 30 min, and 1, 2, 4, 8, 12, and 24 h after competition of administration. In Study 3, landiolol hydrochloride was administered with escalating doses. 16 subjects were randomly allocated to the LM group (n＝6), consisting of Dose L (a 1-min loading infusion at 30 mg/kg/min, followed by a 10-min continuous infusion at 10 mg/kg/min) and then Dose M (a 1-min loading infusion at 60 mg/kg/min, followed by a 10-min continuous infusion at 20 mg/kg/min), or the MH group (n＝6), consisting of Dose M and then Dose H (a 1-min loading infusion at 125 mg/kg/min, followed by a 10-min continuous infusion at 40 mg/kg/min), and the placebo group (n＝4). Seventeen blood samples were drawn from the vein of each subject before dosing, and at 1, 2, 6, 11, 12, 13, 17, and 22 min, and 24 h after initiation of administration, and at 2, 5, 10, and 30 min, and 1, 4, and 8 h after completion of administration.
Blood concentration of landiolol hydrochloride: Blood concentration of landiolol hydrochloride was quantified by high-performance liquid chromatography (HPLC), as outlined below. Initially, landiolol hydrochloride was extracted from blood in ethanol. The supernatant was then evaporated. The blood sample residues were extracted by C18 solid-phase extraction. The eluent was extracted with ethyl acetate under mild alkaline conditions. After evaporation of the organic layer contained landiolol hydrochloride, the residue was reconstituted with the mobile phase and injected into the HPLC with an ultra-violet system. The quantitative range for landiolol hydrochloride concentration in the blood was 50-10 4 ng/mL. This method was validated for accuracy, precision, sensitivity, and specificity.
Population pharmacokinetic model development of landiolol hydrochloride: The population pharmacokinetic model was developed using the nonlinear mixed-effect modeling software NONMEM (Ver.V level 1.1).
11)
The first order conditional estimation with interaction method was used for parameter estimation. After investigation of one-, two-, and three-compartment models, the concentration time course of landiolol hydrochloride was best described by a two-compartment model. The model parameters were total body clearance (CL: mL/min/kg), distribution volume of the central compartment (V1: mL/kg), inter-compartmental clearance (Q: mL/min/kg), distribution volume of the peripheral compartment (V2: mL/kg), and lag time (ALAG: min). The inter-individual variability in pharmacokinetic parameters of landiolol hydrochloride was investigated using an additive and exponential error model. The residual variability was also investigated using an additive, exponential and mixed error model. Exploratory analysis of covariates was not conducted because the pharmacokinetic parameters of landiolol hydrochloride were estimated as values per kg of weight and all laboratory test values of the population who was young healthy volunteers were within the normal range.
The minimum value of the NONMEM objective function (OBJ) was used as a statistic to choose suitable models during the model-building process. The difference in OBJ between one model and the other approximates a x 2 distribution with a degree of freedom which is the difference between the number of parameters. A difference in OBJ of 3.84 for 1 degree of freedom (pº0.05) was considered statistically significant in the model-building process.
Model evaluation: In order to confirm that the final model actually reflects the observed blood concentrations, the predicted values were plotted versus the observed values and conditional weighted residuals 12) for a population model. The individual post hoc estimates of random effects (h) for a population model versus studies (study1-3) were examined to determine if there was any study effect. A bootstrap method 13) and a leave-one-out cross validation method 14, 15) were used to evaluate the stability and robustness of the population model. In the bootstrap method, two hundred data sets were reconstructed by re-sampling from the original data. The mean parameter estimates obtained from bootstrap replications with successful runs (both estimation and covariance step were successfully converged) were compared with those obtained from the original data set. Subsequently, the population model was also evaluated by the leave-one-out cross validation method. Briefly, one subject was sequentially dropped from the original data set and the population model was applied. The parameter estimates obtained from each of the 47 data sets were compared to investigate for outliers.
Results
A total of 420 blood concentration data points collected from 47 healthy male subjects were used for the population pharmacokinetic analysis. Figure 1 shows a typical time-course of blood concentration of landiolol hydrochloride. The concentration time course of landiolol hydrochloride was best described by a two-compartment model with lag time based on the Akaike Information Criterion (AIC) and diagnostic plots. The lag time was a necessary component to each model because its incorporation significantly improved fitting. AIC of one-, two-, and three-compartment models were 5003.740, 4863.628, and 4864.979, respectively. Thus, the two- Figure 2 shows the parameter estimates from the population pharmacokinetic analysis performed by fitting the population model to the data set generated by a leaveone-out method (one subject was sequentially dropped from the original data set). Visual evaluation of the graph indicated that the estimated values of Q, V2, and vV1 2 from the data set excluding subject No. 10 had deviated. Consequently, the effects of blood concentration data from subject No. 10 on the predicted blood concentration based on the population model were evaluated. Figure 3 shows the predicted values based on the parameter estimates obtained from the full data containing subject No. 10 and the data excluding subject No. 10.
The predicted values between the two were different beyond 30 min after completion of administration.
Since the results of model evaluation indicated that the data at 30 and 60 min after completion of administration in subject No.10 were outliers, a model was reconstructed by excluding these two data points. As a result, subject No. 25 and 35 who have blood concentration data at 30 min after completion of administration were also found to be outliers based on a leave-one-out cross validation. Therefore, the model was reconstructed by excluding these two additional points.
The concentration time course of landiolol hydrochloride was best described by a two-compartment model. AIC of one-and two-compartment models were 4877.973 and 4827.113, respectively. NONMEM analysis using three-compartment model did not converge. Additional pharmacokinetic parameters such as ALAG and random variables for inter-individual variability were consistent with the former population model (full data model). Table 3 shows the parameter estimates for the final model. The final parameters were total body clearance (CL: 36.6 mL/min/kg), distribution volume of the central compartment (V1: 101 mL/kg), inter-compartmental clearance (Q: 16.1 mL/min/kg), distribution volume of the peripheral compartment (V2: 55.6 mL/kg), and lag time (ALAG: 0.82 min). The inter-individual variability in the CL and V1 were 21.8% and 46.3%, respectively. The residual variability was 22.1%. The parameter estimates for the final model and the results of the bootstrap validation step are listed in Table 3 . The mean of parameters obtained from bootstrap samples were within ±15% difference from the population pharmacokinetic parameters obtained from the original data except for Q and vV1 2 . The differences of Q and vV1 2 between the original data and bootstrap samples were -31.7% and -41.1%, respectively. Outlier was not observed on the visual evaluation from leave-one-out cross validation (Fig. 4) . In order to confirm that the final model actually reflects the observed blood concentrations, the predicted values (PRED) were plotted versus the observed values (DV) and conditional weighted residuals (CWRES) plots for the final model (Fig. 5) . No obvious bias pattern was apparent in the plot of predicted blood concentration versus the conditional weighted residuals. The individual post hoc estimates of random effects (h) of CL and V1 for the final model versus studies were shown in Figure 6 . These estimates were consistent across the 3 studies.
Discussion
The validity of a population model was evaluated by two methods, a bootstrap method and a leave-one-out cross validation method. Since, in a bootstrap validation, the bootstrap mean values of Q and vV1 2 differed greatly from the parameter estimates obtained from the full data, the presence of outliers was suggested. Consequently, the effects of blood concentration data from each subject on parameter estimates were estimated by a leave-one-out cross validation method. This approach allows the model to be assessed for its descriptive and predictive ability with a split sample or cross validation technique. As a result, the blood concentration data from subject No. 10 were shown to affect the parameter estimates of Q, V2, and vV1
2
. Reviewing the blood landiolol hydrochloride concentration-time profile, blood concentration from subject No. 10 was detected at 30 and 60 min after completion of administration, whereas the concentration from other subjects except for subject No. 25 and 35 was below the limit of quantification beyond 30 min after completion of administration (blood concentration from subject No. 25 and 35 was detected until 30 min after completion of administration). Moreover, elimination of blood landiolol hydrochloride concentration in subject No. 10, 25, and 35 exhibited a relatively gradual decline beyond 15 min after completion of administration and was clearly biphasic. In spite of the rapid elimination of the drug, the blood concentrations in these subjects were detected at 30 and 60 minutes after completion of administration, presumably because these subjects were included in the maximum dosing group. It was obvious from the process of leave-one-our cross validation that the four blood concentration data of terminal phase from subject No. 10, 25, and 35 affected parameter estimates of Q, V2 and vV1
. Landiolol hydrochloride is a ultra short-acting b1-adrenergic receptor blocking agent which has an elimination half-life of about 4 min. 2) Therefore, the blood concentrations beyond 30 min after completion of administration are unlikely to affect the efficacy and safety. Accordingly, it was considered to be adequate to construct the final model by excluding the four blood concentration data.
The two-compartment model was selected as the final model because a central compartment with small distribution volume was necessary to express the rapid increase of blood concentration after loading (2 min after initiation of administration), as shown in Figure 1 . A peripheral compartment which provides a rapid achievement of equilibrium with central compartment was also required to express the reduction of blood concentration to the steady state level by 5 min after initiation of administration. In fact, the sum of V1 (101 mL/kg) and V2 (55.6 mL/kg) in the final model corresponded approximately to V1 (130 mL/kg) in the former model (full data model), while Q in the final model was approximately five-fold higher than that in the former model. Although the bootstrap validation for the final model indicated an improved stability in Q and vV1 2 as compared to those of the former model, they were still rather unstable. It may be attributed to high inter-individual variability in blood concentrations at 1 and 2 min after initiation of administration and was considered to be unimproved by model refinement. On the other hand, the leave-one-out cross validation provided a satisfactory result for the final model. Accordingly, the final model was deemed appropriate for this data set.
The lag time of 0.82 min was incorporated in a twocompartment model. A traditional pharmacokinetic compartmental model (without a lag time) significantly overestimated blood landiolol hydrochloride concentrations in the first blood samples, collected 1 min after initiation of the landiolol hydrochloride administration. This overestimation may have been a result of the inability of the model to track correctly the landiolol hydrochloride concentrations obtained from venous blood sampling. After administration of landiolol hydrochloride in a forearm vein, it mixes within the venous blood, and travels to the right heart. After distribution to the contralateral forearm, the capillary bed of this arm is passed before reaching the point where the blood is sampled. To compensate for the time between the initiation of the administration and the first appearance of landiolol hydrochloride in the venous blood sampled from the contralateral forearm, the lag time was introduced in the pharmacokinetic model. The lag time has also been incorporated in the compartment models for injectable drugs such as propofol 16) and alfentanil 17) , with values of 0.96 min and 1.88 min, respectively, which are in good accordance with that for landiolol hydrochloride.
TCI involves computer control of an infusion pump, and thus the drug dose administered is based on a computerized model. Applications of the TCI system to dosing of propofol, 4, 5) remifentanil, 6) and rocuronium, 7) drugs used for general anesthesia, have been already reported. Of these drugs, remifentanil, which is immediately metabolized by blood-and tissue-nonspecific esterases, has been reported based on the application of a pharmacokinetic model developed from data in healthy adults. 18, 19) Since landiolol hydrochloride is also immediately metabolized by esterases in plasma and liver, the effect of hemodynamic changes, while under anesthesia, to its pharmacokinetics are considered to be limited. Therefore, more effective and safe administration may become available by applying a population pharmacokinetic model of landiolol hydrochloride developed in this study to the TCI system. However, the administration to populations whose metabolic activities and/or distribution volumes may be altered, such as elderly, obese, hepatically or renally impaired, and pregnant patients, should be monitored carefully.
In conclusion, a population pharmacokinetic model of landiolol hydrochloride in healthy subjects was developed. This model was found to be appropriate by a bootstrap validation and a leave-one-out cross validation.
